{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:44:36Z","timestamp":1792669476983,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"DOI":"10.1007\/s40123-026-01501-2","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:27:10Z","timestamp":1792668430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Longitudinal Outcomes of First-Line Aflibercept 8\u00a0mg for Treatment-Na\u00efve Diabetic Macular Edema"],"prefix":"10.1007","author":[{"given":"Bj\u00f8rg","family":"Debes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Tovsg\u00e5rd","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gertrud","family":"Dam-Dalgeir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads Odgaard","family":"M\u00e6ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Vorum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousif","family":"Subhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Trivizki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"\u00d8rskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2150-7754","authenticated-orcid":false,"given":"Lasse J\u00f8rgensen","family":"Cehofski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"1501_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.diabres.2009.10.007","volume":"87","author":"JE Shaw","year":"2010","unstructured":"Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4\u201314. https:\/\/doi.org\/10.1016\/j.diabres.2009.10.007.","journal-title":"Diabetes Res Clin Pract"},{"key":"1501_CR2","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3390\/jpm13030546","volume":"13","author":"Y Subhi","year":"2023","unstructured":"Subhi Y, Potapenko I, Hajari JN, la Cour M. Anti-VEGF treatment of diabetic macular edema in Denmark: incidence, burden of therapy, and forecasting analyses. J Pers Med. 2023;13:546. https:\/\/doi.org\/10.3390\/jpm13030546.","journal-title":"J Pers Med"},{"key":"1501_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cells11213362","volume":"11","author":"J Zhang","year":"2022","unstructured":"Zhang J, Zhang J, Zhang C, Zhang J, Gu L, Luo D, et\u00a0al. Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications. Cells. 2022;11:3362. https:\/\/doi.org\/10.3390\/cells11213362.","journal-title":"Cells"},{"key":"1501_CR4","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","volume":"403","author":"DM Brown","year":"2024","unstructured":"Brown DM, Boyer DS, Wykoff CC, Sakamoto T, Win P, Joshi S, et\u00a0al. Intravitreal aflibercept 8\u00a0mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial. Lancet. 2024;403:1153\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(23)02577-1.","journal-title":"Lancet"},{"key":"1501_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419.pub7","author":"G Virgili","year":"2023","unstructured":"Virgili G, Curran K, Lucenteforte E, Peto T, Parravano M. Anti\u2010vascular endothelial growth factor for diabetic macular oedema: a network meta\u2010analysis. Cochrane Database Syst Rev. 2023. https:\/\/doi.org\/10.1002\/14651858.CD007419.pub7.","journal-title":"Cochrane Database Syst Rev"},{"key":"1501_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2025.101056","volume":"6","author":"LJ Cehofski","year":"2026","unstructured":"Cehofski LJ, Klaassen I, Cao J, Zhou A, \u00d8rskov M, B\u00f8gsted M, et\u00a0al. Serial aqueous humor proteomics in diabetic macular edema. Ophthalmol Sci. 2026;6:101056. https:\/\/doi.org\/10.1016\/j.xops.2025.101056.","journal-title":"Ophthalmol Sci"},{"key":"1501_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.63500\/mv_v30_17","volume":"30","author":"LJ Cehofski","year":"2024","unstructured":"Cehofski LJ, Kojima K, Kusada N, Hansen MS, Muttuvelu DV, Bakker N, et\u00a0al. Central subfield thickness of diabetic macular edema: correlation with the aqueous humor proteome. Mol Vis. 2024;30:17\u201335.","journal-title":"Mol Vis"},{"key":"1501_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2023\/1485059","volume":"2023","author":"YE Han","year":"2023","unstructured":"Han YE, Jo J, Kim YJ, Lee J. Factors affecting intensive aflibercept treatment response in diabetic macular edema: a real-world study. J Diabetes Res. 2023;2023:1\u201311. https:\/\/doi.org\/10.1155\/2023\/1485059.","journal-title":"J Diabetes Res"},{"key":"1501_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoint.2025.100124","volume":"2","author":"A Arnold-Vangsted","year":"2025","unstructured":"Arnold-Vangsted A, Rosen\u00f8rn EA, Butler ETS, Anguita R, Anjos RS, Cehofski LJ, et\u00a0al. Evidence for whom? A systematic review of eligibility criteria in RCTs of anti-VEGF for neovascular age-related macular degeneration. AJO Int. 2025;2:100124. https:\/\/doi.org\/10.1016\/j.ajoint.2025.100124.","journal-title":"AJO Int"},{"key":"1501_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377\u201381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010.","journal-title":"J Biomed Inform"},{"key":"1501_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et\u00a0al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208.","journal-title":"J Biomed Inform"},{"key":"1501_CR12","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/aos.16709","volume":"102","author":"Y Subhi","year":"2024","unstructured":"Subhi Y, Schneider M, Hajari JN, la Cour M. Injection burden and treatment intervals of aflibercept in observe-and-plan regimen for neovascular age-related macular degeneration. Acta Ophthalmol. 2024;102:821\u20137. https:\/\/doi.org\/10.1111\/aos.16709.","journal-title":"Acta Ophthalmol"},{"key":"1501_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2023.101220","volume":"98","author":"SK Szeto","year":"2024","unstructured":"Szeto SK, Lai TY, Vujosevic S, Sun JK, Sadda SR, Tan G, et\u00a0al. Optical coherence tomography in the management of diabetic macular oedema. Prog Retin Eye Res. 2024;98:101220.","journal-title":"Prog Retin Eye Res"},{"key":"1501_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2026.101087","volume":"6","author":"J Spindler","year":"2026","unstructured":"Spindler J, Artemiev D, Pfister IB, Schild C, Tillmann A, Heck K, et\u00a0al. Twelve-month outcomes using aflibercept 8\u00a0mg in treatment-na\u00efve and pretreated diabetic macular edema: a Swiss Retina Research Network report. Ophthalmol Sci. 2026;6:101087. https:\/\/doi.org\/10.1016\/j.xops.2026.101087.","journal-title":"Ophthalmol Sci"},{"key":"1501_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-026-01395-0","author":"F Menna","year":"2026","unstructured":"Menna F, Calabro M, Guillot A, De Luca L, Meduri A, Baldascino A, et\u00a0al. Functional real-world outcomes of aflibercept 8\u00a0mg versus faricimab after loading phase in diabetic macular edema. Ophthalmol Ther. 2026. https:\/\/doi.org\/10.1007\/s40123-026-01395-0.","journal-title":"Ophthalmol Ther"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01501-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01501-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01501-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:27:10Z","timestamp":1792668430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01501-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":15,"alternative-id":["1501"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01501-2","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"23 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No financial support was received for the collection, analysis, and dissemination of the data. Bj\u00f8rg Debes, Sarah Tovsg\u00e5rd Kristensen, Celine Lee, Mads Odgaard M\u00e6ng, Line Petersen, Omer Trivizki and Marie \u00d8rskov have nothing to disclose. Henrik Vorum: Bayer (Advisory Board). Lasse J\u00f8rgensen Cehofski: AbbVie (Research grant, speaker honorarium), Bayer (Advisory Board, speaker honorarium), Roche (Research grant, Advisory Board). Yousif Subhi is a Section Editor for Ophthalmology and Therapy. Yousif Subhi was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study obtained approval from the North Denmark Region prior to data collection. The approval was granted in accordance with Danish Data Protection Regulations (GDPR, Article 30) and Aalborg University Hospital research guidelines. The study was conducted in accordance with the Helsinki declaration.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}